MedTrace Logo

AMT-562 in Patients With Selected Advanced Solid Tumors

NCT06199908 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2024-07-26

No results posted yet for this study

Summary

This is a first-in-human, non-randomized, open-label, multicenter Phase 1 study of AMT-562 in patients with advanced solid tumors.

Conditions

Interventions

DRUG

AMT-562

Administered AMT-562 for injection intravenously

Sponsors & Collaborators

  • Multitude Therapeutics (Australia) Pty Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-20
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06199908 on ClinicalTrials.gov